Defining biology and recurrence risk in prostate cancers treated by neoadjuvant chemohormonal therapy

J Natl Cancer Inst. 2024 Jan 10;116(1):12-14. doi: 10.1093/jnci/djad192.
No abstract available

Publication types

  • Research Support, N.I.H., Intramural
  • Editorial
  • Comment

MeSH terms

  • Biology
  • Docetaxel
  • Humans
  • Male
  • Neoadjuvant Therapy*
  • Prostatic Neoplasms* / drug therapy
  • Risk

Substances

  • Docetaxel